P.0153 Association Between Negative and Cognitive Symptoms and Apolipoprotein A1 and B Plasma Levels in Schizophrenia

In cardiomyocytes, Ca2 + plays a central role in governing both contraction and signaling events that regulate gene expression. Current evidence indicates that discrimination between these two critical functions is achieved by segregating Ca2 + within subcellular microdomains: transcription is regulated by Ca2 + release within nuclear microdomains, and excitation–contraction coupling is regulated by cytosolic Ca2 +. Accordingly, a variety of agonists that control cardiomyocyte gene expression, such as endothelin-1, angiotensin-II or insulin-like growth factor-1, share the feature of triggering nuclear Ca2 + signals. However, signaling pathways coupling surface receptor activation to nuclear Ca2 + release, and the phenotypic responses to such signals, differ between agonists. According to earlier hypotheses, the selective control of nuclear Ca2 + signals by activation of plasma membrane receptors relies on the strategic localization of inositol trisphosphate receptors at the nuclear envelope. There, they mediate Ca2 + release from perinuclear Ca2 + stores upon binding of inositol trisphosphate generated in the cytosol, which diffuses into the nucleus. More recently, identification of such receptors at nuclear membranes or perinuclear sarcolemmal invaginations has uncovered novel mechanisms whereby agonists control nuclear Ca2 + release. In this review, we discuss mechanisms for the selective control of nuclear Ca2 + signals with special focus on emerging models of agonist receptor activation.